HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,008,595 | +284.8% | 26,403 | +473.2% | 0.00% | +300.0% |
| Q4 2022 | $262,082 | +52.4% | 4,606 | +18.0% | 0.00% | 0.0% |
| Q2 2022 | $172,000 | +27.4% | 3,902 | +15.6% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | +3.1% | 3,374 | +3.9% | 0.00% | 0.0% |
| Q4 2021 | $131,000 | +11.0% | 3,247 | +12.0% | 0.00% | 0.0% |
| Q3 2021 | $118,000 | +0.9% | 2,898 | +12.1% | 0.00% | 0.0% |
| Q2 2021 | $117,000 | +8.3% | 2,585 | -0.1% | 0.00% | 0.0% |
| Q1 2021 | $108,000 | +30.1% | 2,588 | +32.4% | 0.00% | 0.0% |
| Q4 2020 | $83,000 | +84.4% | 1,955 | +15.0% | 0.00% | 0.0% |
| Q3 2020 | $45,000 | -4.3% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $47,000 | +80.8% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $26,000 | -10.3% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $29,000 | +7.4% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $27,000 | +8.0% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $25,000 | -19.4% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $31,000 | – | 1,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |